LAPTM5 and metabolic dysfunction-associated steatohepatitis: In summary, in this study, we identified LAPTM5 as an unreported suppressor of NASH that could negatively regulate the p38/c-JNK pathway by promoting CDC42 lysosome degradation in hepatocytes.